Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Effect of statin on MS progression not related to cholesterol reduction

A computational analysis of research data has shown that the effect of simvastatin in delaying progression of an advanced form of multiple sclerosis is independent of its effect on cholesterol levels.

Man with multiple scerosis in a wheelchair


The effect of simvastatin in delaying progression of multiple sclerosis is likely not related to its effect on cholesterol levels

A previously demonstrated effect of simvastatin in delaying progression in an advanced form of multiple sclerosis (MS) is not related to its effect on serum cholesterol levels, a study published in PNAS (28 May 2019) has suggested[1].

The research took data from a trial where 140 people with secondary progressive MS were randomly assigned to either simvastatin or placebo for two years.

Using computational methods, the researchers programmed two scenarios — one where the effects of simvastatin on expanded disability status score and brain atrophy were directly related to total serum cholesterol and one where they were not.

They found that the second model was most likely, indicating the effects of simvastatin in MS were likely due to intermediates in the cholesterol synthesis pathway and not circulating cholesterol levels. However, the mechanism is still unknown.

“Although this study cannot provide a final answer as to what exactly is the reason for the success of statins in progressive MS, it directs future researchers toward certain pathways,” said lead author Arman Eshaghi, a researcher at UCL Queen Square Institute of Neurology.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206651

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.